Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Exelixis, Inc.NASDAQ: EXEL

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jul 2026

Weighted avg shares (diluted) declines year over year

Q2 FY2026 weighted avg shares (diluted) of 259.68M shares fell 8.7% year over year, behind the -6.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.7% toward the trailing-twelve-month pace of -6.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJul 2026
259.68M-2.9% QoQ
Last fiscal yearJan 2026
281.86M-4.8% YoY
LTMJul 2026
271.85M-6.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.7%——
1 year-4.8%——
3-year CAGR-4.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
281.86M USD
Year-over-year change
-4.8%
4-year CAGR
-3.3%

Weighted Avg Shares (Diluted) vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 weighted avg shares (diluted) of 271.85M shares is the 3rd highest of the 8 companies compared; the peer median is 197.09M shares.
  • Its year-over-year change of -6.1% is the lowest of 7, against a peer median of +2.6%.
  • Over three fiscal years its annual growth of -4.6% compares with a peer median of +1.0%.
EXEL Competitors Peer median
Weighted Avg Shares (Diluted) for EXEL and competitors
Company Period LTM YoY 3-year CAGR
AZNAstraZeneca PLCLTM Sep 20261.56B +0.0%+0.0%
GMABGenmab A/SLTM Jun 2026637.25M —-1.7%
EXELExelixis, Inc.LTM Jul 2026271.85M -6.1%-4.6%
INCYIncyte CorporationLTM Jun 2026205.31M +3.9%-3.6%
RVMDRevolution Medicines, Inc.LTM Jun 2026197.09M +10.9%+33.1%
HCMHUTCHMED (China) LimitedLTM Jun 2025174.57M +1.2%+1.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.96M +6.3%+3.0%
Peer median (excluding EXEL) 197.09M+2.6%+1.0%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.43B1.61B1.83B2.17B2.32B
Cost of Revenue52.87M57.91M72.55M76.22M83.7M
Gross Profit1.38B1.55B1.76B2.09B2.24B
Gross Margin96.3%96.4%96.0%96.5%96.4%
Research & Development693.72M891.81M1.04B910.41M825M
Selling, General & Admin401.72M459.86M542.71M492.13M518.73M
Operating Expenses1.1B1.35B1.59B1.49B1.36B
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
EBITDA307.78M255.23M283.24M718.75M921.76M
EBITDA Margin21.4%15.8%15.5%33.1%39.7%
Operating Income286.67M201.48M170.89M604.62M872.19M
Operating Margin20.0%12.5%9.3%27.9%37.6%
Interest Income7.67M33.07M86.54M77.16M69.21M
Interest Expense00000
Other Income / Expenses7.49M32.87M86.64M77.02M69.02M
Income Before Tax294.15M234.35M257.52M681.64M941.21M
Pre-Tax Margin20.5%14.5%14.1%31.4%40.6%
Income Tax Expense63.09M52.07M49.76M160.37M158.64M
Net Income231.06M182.28M207.77M521.27M782.57M
Net Margin16.1%11.3%11.4%24.0%33.7%
EPS (Basic)0.730.570.651.802.88
EPS (Diluted)0.720.560.651.762.78
Weighted Avg Shares314.88M321.53M318.15M290.03M271.57M
Weighted Avg Shares (Diluted)322.36M324.56M321.46M296.13M281.86M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.